Upcoming
Beyond the Fund: How Biotech Venture Builders Are Redefining VC Model
Thursday, May 29th, 2025, 10:00 AM ET
Featured Speakers
.png)
Ken Belotsky
Co-founder at Negev Labs
.png)
Shlomi Raz
Co-founder at Negev Labs
David Socks
Managing Partner, Mountainfield Venture Partners
Oops! Something went wrong while submitting the form.
About
The traditional VC model is broken.
Tiny stakes. Zero control. Sprayed bets. 10-year fund cycles. LPs last in line.
At Negev Labs, we said no to that game.
We build biotech companies from scratch—around underpriced IP with human use data. Our team does the heavy lifting—sourcing, building, de-risking. But our investors don’t just get a passive fund return…
They get the same economic upside as co-founders in each spinout.
What You’ll Learn:
- The limitations of conventional VC models in biotech.
- How venture builders like Negev Labs are creating high-conviction biotech ventures.
- Strategies for aligning investor interests with company success.
- Insights into sourcing, building, and de-risking biotech startups.
Date & Time:
Thursday, May 29th, 2025, 10:00 AM EST